A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Recruiting

Phase 2

Inavolisib CombinationsA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Sponsor:

Hoffmann-La Roche

Code:

NCT07054190

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Inavolisib

Ribociclib

Letrozole

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-14. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-07-16.